Log in

Lymphoma and Leukaemia Research Review

16 Dec 2020 9:59 AM | Anonymous member (Administrator)

Issue 52 of Lymphoma and Leukaemia Research Review

This issue begins with research reporting good tolerability of BR (bendamustine, rituximab) in patients aged ≥80 years with CLL, with efficacy and safety similar to that seen in younger patients as long as carefully adapted dosing is applied.

The PDF can be viewed here, and now you can also view the issue online.


CONTACT

Haematology Society of Australia and New Zealand (HSANZ)
145 Macquarie Street, Sydney NSW 2000
Tel: 02 8097 8114


FOLLOW US

Copyright © 2020 Haematology Society of Australia & New Zealand (HSANZ). All Rights Reserved.

Powered by Wild Apricot Membership Software